Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Japanese Subjects with Moderate to Severe Hidradenitis Suppurativa
NCT02904902Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT02904902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02904902.